Big Kahuna, the list of drugs and development stages mentioned are favorable. That being said, you still favor a big pharma partnership for B-ABSSSI at a young age of our uplisting?
BioHedge points out a stock run in his post for below:
For reference check out ACAD's chart between Sept 1, 2012 and Oct 1, 2013. There was not a lot of correction going on, as the stock went from ~$1.75 to ~$30/share.
Looking at ACAD's cash on hand says 354 million mrq and 2.2 billion market value, we do have more pipeline than them. My feeling is we need to show a good cash reserve if we want to stay stable SP on Nasdaq or NYSE and partnership would be very helpful in this regard.
Fund buying will push it up, but good cash balance is added security in confidence to get as many trials done as possible over next 2-3 years.
Market Data 
Markets 
AI
